| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| R&D Expense | $14.7M | +14.1% |
| SG&A Expense | $4.4M | -6.4% |
| Operating Income | -$19.0M | -8.7% |
| Pre-tax Income | -$18.8M | -7.8% |
| Income Tax | $2K | +0.0% |
| Net Income | -$18.8M | -7.8% |
| EPS (Basic) | -$0.51 | +34.6% |
| EPS (Diluted) | -$0.51 | +34.6% |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $13.1M | +41.8% |
| Accounts Receivable | $142K | +0.0% |
| Current Assets | $13.5M | +39.4% |
| Total Assets | $18.7M | +35.7% |
| Current Liabilities | $1.3M | -13.1% |
| Total Liabilities | $1.7M | -27.0% |
| Stockholders' Equity | $17.1M | +48.0% |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$15.7M | -12.7% |
| Capital Expenditures | $2.5M | +46.6% |
| Investing Cash Flow | -$2.5M | -46.6% |
| Financing Cash Flow | $22.1M | +4.7% |
| Free Cash Flow | -$18.2M | -16.4% |